Molecular mimetics of polysaccharide epitopes as vaccine candidates for prevention of Neisseria meningitidis serogroup B disease.
Neisseria meningitidis is a major cause of meningitis and sepsis. Despite nearly 25 years of work, there is no promising vaccine candidate for prevention of disease caused by meningococcal B strains. This review summarizes newer approaches for eliciting protective meningococcal B immune responses, including the use of molecular mimetics of group B polysaccharide and conserved membrane proteins as immunogens. The capsular polysaccharide of this organism is conserved and serum antibody to this capsule confers protection against disease. However, the immunogenicity of meningococcal B polysaccharide-based vaccines is poor. Further, a portion of the antibody elicited has autoantibody activity. Recently, our laboratory produced a panel of murine monoclonal antibodies (Mabs) that react specifically with capsular polysaccharide epitopes on meningococcal B that are distinct from host polysialic acid. These Mabs elicit complement-mediated bactericidal activity and confer passive protection in animal models. The anti-capsular Mabs were used to identify molecular mimetics from phage display peptide libraries. The resulting peptides were antigenic mimetics as defined by binding to the Mabs used to select them but, to date, are poor immunogenic mimetics in failing to elicit anti-capsular antibodies.
Moe
G R
GR
Children's Hospital Oakland Research Institute, 747 52nd Street, Oakland, CA 94609, USA.
Tan
S
S
Granoff
D M
DM
D000818:Animals; D001428:Bacterial Vaccines / Q000737:chemistry / Q000276:immunology*; D000939:Epitopes / Q000276:immunology; D008589:Meningococcal Infections / Q000382:microbiology / Q000517:prevention & control*; D051379:Mice; D018716:Molecular Mimicry; D009345:Neisseria meningitidis / Q000276:immunology*; D011134:Polysaccharides / Q000737:chemistry / Q000276:immunology*; D012703:Serotyping
D001428:Bacterial Vaccines; D000939:Epitopes; D011134:Polysaccharides